Expression and prognostic significance of iNOS in uveal melanoma

International Journal of Cancer

Volumn 126, Issue 11, 2010, Pages 2682-2689

  Johansson, C Christian ^a   Mougiakakos, Dimitrios ^a   Trocme, Eric ^a,b   All Ericsson, Charlotta ^b   Economou, Mario A ^b   Larsson, Olle ^a   Seregard, Stefan ^b   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Ophthalmic Pathology and Oncology Service   (Sweden)

Author keywords

iNOS; Prognostic factor; Survival; Uveal melanoma

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UVEA MELANOMA; AGED; CANCER INVASION; CHOROID TUMOR; ENZYMOLOGY; GENETICS; MELANOMA; METASTASIS; MIDDLE AGED; NECROSIS; PATHOLOGY; PREDICTION AND FORECASTING; SCLERA; UVEA TUMOR;

AGED; CHOROID NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE TYPE II; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SCLERA; UVEAL NEOPLASMS;

EID: 77951219450     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24984     Document Type: Article

References (38)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-251
2. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:962-965
3. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72:2219-2223 (Pubitemid 23280150)
4. Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. AJR Am J Roentgenol 1991;157:1279-1281
5. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983;52:334-336
6. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665-1670
7. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005;23:8076-8080 (Pubitemid 46657410)
8. Hibbs JB,Jr.Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157: 87-94. (Pubitemid 19004828)
9. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269
10. Hibbs JB, Jr. Synthesis of nitric oxide from L-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res Immunol 1991; 142:565-9; discussion 96-98
11. Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev 2000;173:17-26. (Pubitemid 30095207)
12. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-156 (Pubitemid 33585926)
13. Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 1997;379:211-218 (Pubitemid 27450541)
14. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res 2001;61:318-326 (Pubitemid 32095733)
15. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004;279:288-298
16. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352-1354 (Pubitemid 24108080)
17. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-44
18. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119:861-866 (Pubitemid 44051450)
19. Johansson CC, Egyhazi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, Nilsson B, Garberg L, Tuominen R, Linden D, Stolt MF, Hansson J, et al. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother 2009;58:1085-1094
20. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, Martins C, Fernandes BF, Burnier MN, Jr. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008;14:951-956
21. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995;55:727-730
22. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000;6:4768-4775 (Pubitemid 32110418)
23. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:1414-1421 (Pubitemid 32520728)
24. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:505-510
25. Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:2153-2156 (Pubitemid 32848839)
26. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol 2003;74:179-185
27. Caruso C, Mohn C, Karara AL, Rettori V, Watanobe H, Schioth HB, Seilicovich A, Lasaga M. Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats. Neuroendocrinology 2004;79:278-286 (Pubitemid 38969873)
28. Delgado M. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J Biol Chem 2003;278:27620-27629 (Pubitemid 36899948)
29. Lee H, Park K, Kim JS, Lee SJ. Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro. J Neurosci Res 2009;87:171-178
30. Thody AJ. alpha-MSH and the regulation of melanocyte function. Ann NY Acad Sci 1999;885:217-229
31. Vila-del Sol V, Diaz-Munoz MD, Fresno M. Requirement of tumor necrosis factor alpha and nuclear factor-kappaB in the induction by IFN-gamma of inducible nitric oxide synthase in macrophages. J Leukoc Biol 2007;81:272-283 (Pubitemid 46021277)
32. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-122
33. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-190 (Pubitemid 30058750)
34. Ostendorf T, Van Roeyen C, Westenfeld R, Gawlik A, Kitahara M, De Heer E, Kerjaschki D, Floege J, Ketteler M. Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. J Am Soc Nephrol 2004;15:2307-2319 (Pubitemid 39159331)
35. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-119 (Pubitemid 39345400)
36. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide 2008;19:133-137
37. Cryan LM, Paraoan L, Hiscott P, Damato BE, Grierson I, Gray D, Farrell M, Doherty GA, Fitzgerald DJ, O'Brien C. Expression of COX-2 and prognostic outcome in uveal melanoma. Curr Eye Res 2008;33:177-184 (Pubitemid 351302204)
38. Figueiredo A, Caissie AL, Callejo SA, McLean IW, Gold P, Burnier MN, Jr. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can J Ophthalmol 2003; 38:352-356 (Pubitemid 37295119)